Delivery Order SPE2DR25D2002-SPE2DR26FBSG8
Award Date 12/2/25
Potential Completion Date 12/3/25
Potential Value $68K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a $37,755.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 8, 2025, with completion due by December 9, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine, and this delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation....
- The Defense Logistics Agency (DLA) awarded a $72,453.28 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of October 22, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside structure. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,057.16 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on October 15, 2025, with completion scheduled for October 16, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract covers the supply of HEPLISAV-B, a recombinant hepatitis B vaccine, which...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,948.68 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a procurement of hepatitis B vaccine supplies to support federal medical requirements. The order is being fulfilled from AmerisourceBergen's place of performance in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, valued at $10,347.75 under a firm fixed-price contract. This non-set-aside delivery order was awarded on December 2, 2025, with an ultimate completion date of December 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $1,684.96, with an ultimate completion date of June 25, 2025. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The product will be performed at AmerisourceBergen's Conshohocken location. HEPLISAV-B is a recombinant...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,684.96 to supply HEPLISAV-B 20 mcg/0.5 mL syringes on May 27, 2025. The order is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award does not utilize a set-aside designation and was competitively awarded. This delivery order is a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,699.20 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on open competition. Performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $22,056.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply procurement executed under a non-set-aside vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...